Gabriele Berman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gabriele Berman has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Susan Patricia Mollan
Metabolism and Systems Science, School of Medical Sciences, University of Birmingham, Birmingham, UK
26 shared publications - Michael Lowe
Birmingham Neuro-Ophthalmology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
20 shared publications - Alexandra Jean Sinclair
Metabolism and Systems Science, University of Birmingham, Birmingham, UK
6 shared publications Erind Alushaj
4 shared publicationsSarah M. Simpson
4 shared publications- Charles Page
University of Birmingham Medical School, School of Medical Sciences, University of Birmingham, Birmingham, UK
3 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Springer Nature in Eye
- Vol. 40 (16) , 2633-2640
Optical coherence tomography imaging device comparison study in papilloedema secondary to idiopathic intracranial hypertension
Background: Optic nerve imaging assessing papilloedema is an increasingly important clinical measure to guide treatment. The aim of this study was to understand the agreement between two commonly used OCT devices and whether pooling of papilloedema OCT imaging data could be easily facilitated. Methods: People living with idiopathic intracranial hypertension (IIH) underwent non-dilated same-day OCT imaging performed on Spectralis SD-OCT (Heidelberg Engineering, Heidelberg, Germany) and Cirrus 6000 OCT (Carl Zeiss Meditec, Dublin, CA). Comparable measurements were collected (retinal nerve fibre layer (RNFL), maximum height of the optic nerve head and macular ganglion cell layer assessment). Bland-Altman plots were constructed, intraclass correlation coefficient (ICC) and Pearson correlation coefficient were calculated. Results: Ninety-seven people with a definite diagnosis of IIH were included: 95% were women with a mean age of 31 years. Mean global RNFL thickness was 117.4μm (SD 41.6) on the Spectralis platform and 122.5μm (SD 53.8) on the Cirrus platform. There was excellent agreement between the devices for RNFL thickness measurements (ICC = 0.922), although the Bland-Altman plot revealed increasing discrepancy at higher RNFL thicknesses. Maximum disc height displayed good agreement (ICC = 0.882) between devices. There was a very strong positive correlation between Spectralis GCL volume and Cirrus GC-IPL thickness(r = 0.911). Conclusions: This OCT imaging dataset spanning a range of papilloedema severity in people with a definite diagnosis of IIH showed good relative agreement of RNFL measurements between Spectralis and Cirrus devices at RNFL thicknesses close to normal, but greater variance with more severe papilloedema. RNFL measurements from the two devices cannot be used interchangeably. Macular GCL assessments showed a strong positive linear correlation.
- 22 September 2026
- Published by Springer Nature in Eye
- Vol. 40 (16) , 2633-2640
Open AccessOptical coherence tomography imaging device comparison study in papilloedema secondary to idiopathic intracranial hypertension
Background: Optic nerve imaging assessing papilloedema is an increasingly important clinical measure to guide treatment. The aim of this study was to understand the agreement between two commonly used OCT devices and whether pooling of papilloedema OCT imaging data could be easily facilitated. Methods: People living with idiopathic intracranial hypertension (IIH) underwent non-dilated same-day OCT imaging performed on Spectralis SD-OCT (Heidelberg Engineering, Heidelberg, Germany) and Cirrus 6000 OCT (Carl Zeiss Meditec, Dublin, CA). Comparable measurements were collected (retinal nerve fibre layer (RNFL), maximum height of the optic nerve head and macular ganglion cell layer assessment). Bland-Altman plots were constructed, intraclass correlation coefficient (ICC) and Pearson correlation coefficient were calculated. Results: Ninety-seven people with a definite diagnosis of IIH were included: 95% were women with a mean age of 31 years. Mean global RNFL thickness was 117.4μm (SD 41.6) on the Spectralis platform and 122.5μm (SD 53.8) on the Cirrus platform. There was excellent agreement between the devices for RNFL thickness measurements (ICC = 0.922), although the Bland-Altman plot revealed increasing discrepancy at higher RNFL thicknesses. Maximum disc height displayed good agreement (ICC = 0.882) between devices. There was a very strong positive correlation between Spectralis GCL volume and Cirrus GC-IPL thickness(r = 0.911). Conclusions: This OCT imaging dataset spanning a range of papilloedema severity in people with a definite diagnosis of IIH showed good relative agreement of RNFL measurements between Spectralis and Cirrus devices at RNFL thicknesses close to normal, but greater variance with more severe papilloedema. RNFL measurements from the two devices cannot be used interchangeably. Macular GCL assessments showed a strong positive linear correlation.
- 21 September 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
Reply: Optic Nerve Sheath Compartmentation as a Mechanism for Idiopathic Intracranial Hypertension Without Papilledema
Was not provided for this article.
- 21 September 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
Reply: Optic Nerve Sheath Compartmentation as a Mechanism for Idiopathic Intracranial Hypertension Without Papilledema
Was not provided for this article.
- Open Access
- 3 July 2026
- Published by Springer Nature in Eye
Infographic: efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity
- 3 July 2026
- Published by Springer Nature in Eye
Open AccessInfographic: efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity
- Open Access
- 24 June 2026
- Published by Springer Nature in Eye
- p. 1-2
Infographic: efficacy and safety of intravitreal siRNA therapy for acute NAION (QRK207 trial)
- 24 June 2026
- Published by Springer Nature in Eye
- p. 1-2
Open AccessInfographic: efficacy and safety of intravitreal siRNA therapy for acute NAION (QRK207 trial)
- Open Access
- 23 June 2026
- Published by Springer Nature in Eye
Infographic: optic nerve decompression surgery for NAION (IONDT Trial)
- 23 June 2026
- Published by Springer Nature in Eye
Open AccessInfographic: optic nerve decompression surgery for NAION (IONDT Trial)
- 1 June 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 46 (2) , 149-164
Adult Idiopathic Intracranial Hypertension Without Papilledema: Systematic Review of Literature and Future Perspectives
Background: Idiopathic intracranial hypertension without papilledema (IIHWOP) remains poorly understood. This review summarizes the diagnostic challenges and potential management of adults with IIHWOP. Evidence Acquisition: A detailed search of the scientific literature, combining MeSH and free-text terms, included all English-language papers on PubMed, from inception to June 8, 2025. In this review, we used the term IIHWOP to describe patients without evidence of active or previous papilledema. Results: The diagnosis of IIHWOP is based on elevated lumbar puncture opening pressure accompanied by either sixth cranial nerve palsy or neuroimaging features of intracranial hypertension, which may lack specificity. Clinical presentation frequently mimics primary headache disorders, and lumbar puncture remains an invasive procedure without clear management implications in IIHWOP, as there are no high-quality studies evaluating medical or surgical therapies. Conclusions: Recommendations for investigation and clinical care remain largely inferred from idiopathic intracranial hypertension. Given the absence of evidence for risk of vision loss, invasive procedures should be avoided, and management should focus on weight loss and optimized headache management.
- 1 June 2026
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 46 (2) , 149-164
Adult Idiopathic Intracranial Hypertension Without Papilledema: Systematic Review of Literature and Future Perspectives
Background: Idiopathic intracranial hypertension without papilledema (IIHWOP) remains poorly understood. This review summarizes the diagnostic challenges and potential management of adults with IIHWOP. Evidence Acquisition: A detailed search of the scientific literature, combining MeSH and free-text terms, included all English-language papers on PubMed, from inception to June 8, 2025. In this review, we used the term IIHWOP to describe patients without evidence of active or previous papilledema. Results: The diagnosis of IIHWOP is based on elevated lumbar puncture opening pressure accompanied by either sixth cranial nerve palsy or neuroimaging features of intracranial hypertension, which may lack specificity. Clinical presentation frequently mimics primary headache disorders, and lumbar puncture remains an invasive procedure without clear management implications in IIHWOP, as there are no high-quality studies evaluating medical or surgical therapies. Conclusions: Recommendations for investigation and clinical care remain largely inferred from idiopathic intracranial hypertension. Given the absence of evidence for risk of vision loss, invasive procedures should be avoided, and management should focus on weight loss and optimized headache management.
- Open Access
- 21 May 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (4) , 1036-1037
Progressive weakness but a lot of nerve: noninvasive OCT findings confirm ARSACS
- 21 May 2026
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 61 (4) , 1036-1037
Open AccessProgressive weakness but a lot of nerve: noninvasive OCT findings confirm ARSACS
- Open Access
- 7 April 2026
- Published by Springer Nature in Eye
- Vol. 40 (8) , 1103-1105
A call to develop rigorous standards for excellence in idiopathic intracranial hypertension: RISE-IIH
- 7 April 2026
- Published by Springer Nature in Eye
- Vol. 40 (8) , 1103-1105
Open AccessA call to develop rigorous standards for excellence in idiopathic intracranial hypertension: RISE-IIH
- Open Access
- 30 March 2026
- Published by Springer Nature in Eye
Infographic: teprotumumab for the treatment of active thyroid eye disease
- 30 March 2026
- Published by Springer Nature in Eye
Open AccessInfographic: teprotumumab for the treatment of active thyroid eye disease